{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"ss-31-muscle-loss","title":"SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown","body":"## What's breaking down\n\nMuscle loss with age, often called sarcopenia, involves multiple layers. One key layer is mitochondrial decline inside muscle cells. Mitochondria produce ATP for contraction and repair. With age, they generate more reactive oxygen species, lose efficiency in oxidative phosphorylation, and show reduced ADP sensitivity. This leads to lower energy output, oxidative damage to proteins, and impaired muscle performance and maintenance. If mitochondrial dysfunction outpaces repair mechanisms, muscle mass and strength decline over time.\n\n## Why SS-31 (Elamipretide) might help you\n\n1. If mitochondrial oxidative stress and poor ATP production contribute to your muscle loss, SS-31 binds cardiolipin in the inner mitochondrial membrane. 2. This stabilizes the membrane, improves electron transport chain efficiency, and lowers excess ROS production. 3. Therefore for you: If that layer is part of your problem, SS-31 is discussed because it targets repair (tissue) — not because it masks pain. 4. Better mitochondrial function can support muscle fiber maintenance and fatigue resistance instead of allowing further breakdown.\n\n## How these fit together\n\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer of degeneration. If your profile includes other layers like inflammation or hormonal decline, additional approaches would address those separately.\n\n## What the evidence actually shows\n\nPreclinical studies in aged mice show SS-31 improves skeletal muscle mitochondrial ATP production, reverses age-related redox stress, increases fatigue resistance, and boosts exercise tolerance (Campbell et al. 2019; Siegel et al. 2013). One 2026 rat model of HFpEF found it improved soleus and EDL muscle contractile function and prevented atrophy development. A 2022 mouse study after spinal cord injury found no prevention of muscle atrophy at 7 days. Human data: A randomized trial showed a single dose improved in vivo mitochondrial ATP production in older adult skeletal muscle. Phase 2 trials in primary mitochondrial myopathy showed some exercise gains; phase 3 did not meet primary endpoints on walking distance. In Barth syndrome (mitochondrial cardiolipin disorder with muscle weakness), long-term data supported accelerated approval for muscle strength improvement.\n\n## What scientists say\n\nResearchers note SS-31 rapidly improves ADP sensitivity in aged mitochondria via the adenine nucleotide translocator and stabilizes cardiolipin. They highlight benefits for mitochondrial myopathies and age-related muscle function but emphasize mixed human trial results outside specific genetic conditions. Preclinical consistency on energetics contrasts with translation challenges in broader sarcopenia.\n\n## What people say on Reddit\n\nAnecdotal reports in ME/CFS communities mention perceived muscle strength gains in isolated cases, with one user noting dramatic improvement allowing weight lifting. Others report no noticeable effect or discuss cost barriers from trial doses around 40 mg daily. Discussions often reference mitochondrial myopathy trials and stress pacing alongside any use.\n\n## What people say on X\n\nLimited public posts discuss SS-31 primarily in context of mitochondrial disorders or research updates; few direct anecdotes on general muscle loss appear in recent searches.\n\n## What we do not know\n\nNo large human trials specifically target age-related sarcopenia or general muscle loss. Long-term effects on muscle mass versus function remain unclear outside rare diseases. Optimal duration, combination strategies, and identification of responders based on mitochondrial status need more data.\n\n## Safety and limits\n\nClinical trials report generally good tolerability with subcutaneous or IV administration. Some phase 3 programs showed no major safety signals but lacked efficacy on primary measures. Individual responses vary; it is not approved for general muscle loss. Evidence is strongest in mitochondrial-specific conditions.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/ss-31-muscle-loss/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"SS-31 improves mitochondrial ATP production and exercise tolerance in aged mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Supports mitochondrial repair mechanism for muscle energetics.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A single dose of elamipretide improved in vivo mitochondrial ATP production in older adult skeletal muscle in a randomized trial.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Direct human evidence on mitochondrial function in aging muscle.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet primary endpoints on walking distance or fatigue.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Highlights limits of translation from preclinical to broad human use.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"In a 2026 HFpEF rat model, elamipretide improved muscle contractile function and prevented atrophy.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Recent model linking mitochondrial stabilization to anti-atrophy effects.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"SS-31 did not prevent muscle atrophy 7 days post-SCI in young male mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Shows context-specific limits of benefit.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Anecdotal reports on Reddit include perceived muscle strength gains in some ME/CFS users.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6588449/","title":"Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice","quote":"Treatment with SS-31 restores redox homeostasis, improves mitochondrial quality, and increases exercise tolerance without an increase in mitochondrial content.","summary":"Aged mice study showing mitochondrial and functional muscle benefits.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:51:52.225Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"8dee10a450c5984e52e5a1d663165c59104ca847cae033a249af83eadc8fcad1"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/34264994/","title":"In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial","quote":"In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.","summary":"Identifier corrected 2026-08-05: it read PMID 34242343, which is \"The experiences of family caregivers of people with severe mental illness in the Middle East\". Verified against PubMed that 34264994 is the paper this citation names. Human randomized trial on ATP in aging muscle.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:51:52.225Z","link_status":"ok","quote_status":"unverified","prev":"8dee10a450c5984e52e5a1d663165c59104ca847cae033a249af83eadc8fcad1","hash":"01293e026cd0d26861573930fba64242b2f06b4563c1c4f8a85de8e0e25ba4ca","pmid":"34264994","external_id":"34264994"},{"id":"s3","type":"pubmed","url":"https://www.neurology.org/doi/10.1212/WNL.0000000000005255","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","quote":"Elamipretide increased exercise performance after 5 days of treatment in patients with PMM without increased safety concerns.","summary":"Phase 1/2 and later phase 3 context for PMM.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:51:52.225Z","link_status":"ok","quote_status":"unverified","prev":"01293e026cd0d26861573930fba64242b2f06b4563c1c4f8a85de8e0e25ba4ca","hash":"5ad5d241696237be2b0c6e3943516cf1be0e7340a6e8f77c49371d1c80a36ec1"},{"id":"s4","type":"pubmed","url":"https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.126.014397","title":"Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model","quote":"Elamipretide improved whole muscle contractile function and prevented atrophy development.","summary":"2026 rat study on muscle performance and atrophy prevention.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:51:52.225Z","link_status":"http_403","quote_status":"unverified","prev":"5ad5d241696237be2b0c6e3943516cf1be0e7340a6e8f77c49371d1c80a36ec1","hash":"13b522947f9e8afec6291d738a93503b9fb160230d6909f0d3fa98a6da012102"},{"id":"s5","type":"pubmed","url":"https://physoc.onlinelibrary.wiley.com/doi/10.14814/phy2.15266","title":"SS‐31 does not prevent or reduce muscle atrophy 7 days after a 65 kdyne contusion spinal cord injury in young male mice","quote":"SS-31 did not preserve body mass or hindlimb muscle mass 7 days post-SCI.","summary":"Negative finding in SCI atrophy model.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:51:52.225Z","link_status":"ok","quote_status":"unverified","prev":"13b522947f9e8afec6291d738a93503b9fb160230d6909f0d3fa98a6da012102","hash":"4e13a4e4433ac3fe59e2efcea885e527a8f60b57299915d5f28a63cfe56f5073"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/cfs/comments/1j2upcm/my_experience_treating_my_mecfs_with/","title":"My Experience Treating my ME/CFS with mitochondrial peptides","quote":"i notice very dramatic improvement to muscle strength on the ...","summary":"User reports of muscle strength changes with SS-31.","claim_ids":["c6"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:51:52.225Z","link_status":"ok","quote_status":"unverified","prev":"4e13a4e4433ac3fe59e2efcea885e527a8f60b57299915d5f28a63cfe56f5073","hash":"53f250a3b6773314314d08c8996c3cc9e05d3c63b39dd116dac4e1ed798d0ab0"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":2,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:51:53.770Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown","register":"source_ledger","body":"## What's breaking down\n\nMuscle loss with age, often called sarcopenia, involves multiple layers. One key layer is mitochondrial decline inside muscle cells. Mitochondria produce ATP for contraction and repair. With age, they generate more reactive oxygen species, lose efficiency in oxidative phosphorylation, and show reduced ADP sensitivity. This leads to lower energy output, oxidative damage to proteins, and impaired muscle performance and maintenance. If mitochondrial dysfunction outpaces repair mechanisms, muscle mass and strength decline over time.\n\n## Why SS-31 (Elamipretide) might help you\n\n1. If mitochondrial oxidative stress and poor ATP production contribute to your muscle loss, SS-31 binds cardiolipin in the inner mitochondrial membrane. 2. This stabilizes the membrane, improves electron transport chain efficiency, and lowers excess ROS production. 3. Therefore for you: If that layer is part of your problem, SS-31 is discussed because it targets repair (tissue) — not because it masks pain. 4. Better mitochondrial function can support muscle fiber maintenance and fatigue resistance instead of allowing further breakdown.\n\n## How these fit together\n\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer of degeneration. If your profile includes other layers like inflammation or hormonal decline, additional approaches would address those separately.\n\n## What the evidence actually shows\n\nPreclinical studies in aged mice show SS-31 improves skeletal muscle mitochondrial ATP production, reverses age-related redox stress, increases fatigue resistance, and boosts exercise tolerance (Campbell et al. 2019; Siegel et al. 2013). One 2026 rat model of HFpEF found it improved soleus and EDL muscle contractile function and prevented atrophy development. A 2022 mouse study after spinal cord injury found no prevention of muscle atrophy at 7 days. Human data: A randomized trial showed a single dose improved in vivo mitochondrial ATP production in older adult skeletal muscle. Phase 2 trials in primary mitochondrial myopathy showed some exercise gains; phase 3 did not meet primary endpoints on walking distance. In Barth syndrome (mitochondrial cardiolipin disorder with muscle weakness), long-term data supported accelerated approval for muscle strength improvement.\n\n## What scientists say\n\nResearchers note SS-31 rapidly improves ADP sensitivity in aged mitochondria via the adenine nucleotide translocator and stabilizes cardiolipin. They highlight benefits for mitochondrial myopathies and age-related muscle function but emphasize mixed human trial results outside specific genetic conditions. Preclinical consistency on energetics contrasts with translation challenges in broader sarcopenia.\n\n## What people say on Reddit\n\nAnecdotal reports in ME/CFS communities mention perceived muscle strength gains in isolated cases, with one user noting dramatic improvement allowing weight lifting. Others report no noticeable effect or discuss cost barriers from trial doses around 40 mg daily. Discussions often reference mitochondrial myopathy trials and stress pacing alongside any use.\n\n## What people say on X\n\nLimited public posts discuss SS-31 primarily in context of mitochondrial disorders or research updates; few direct anecdotes on general muscle loss appear in recent searches.\n\n## What we do not know\n\nNo large human trials specifically target age-related sarcopenia or general muscle loss. Long-term effects on muscle mass versus function remain unclear outside rare diseases. Optimal duration, combination strategies, and identification of responders based on mitochondrial status need more data.\n\n## Safety and limits\n\nClinical trials report generally good tolerability with subcutaneous or IV administration. Some phase 3 programs showed no major safety signals but lacked efficacy on primary measures. Individual responses vary; it is not approved for general muscle loss. Evidence is strongest in mitochondrial-specific conditions.","claims":[{"id":"c1","text":"SS-31 improves mitochondrial ATP production and exercise tolerance in aged mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Supports mitochondrial repair mechanism for muscle energetics.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A single dose of elamipretide improved in vivo mitochondrial ATP production in older adult skeletal muscle in a randomized trial.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Direct human evidence on mitochondrial function in aging muscle.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet primary endpoints on walking distance or fatigue.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Highlights limits of translation from preclinical to broad human use.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"In a 2026 HFpEF rat model, elamipretide improved muscle contractile function and prevented atrophy.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Recent model linking mitochondrial stabilization to anti-atrophy effects.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"SS-31 did not prevent muscle atrophy 7 days post-SCI in young male mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Shows context-specific limits of benefit.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Anecdotal reports on Reddit include perceived muscle strength gains in some ME/CFS users.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6588449/","title":"Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice","quote":"Treatment with SS-31 restores redox homeostasis, improves mitochondrial quality, and increases exercise tolerance without an increase in mitochondrial content.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/34242343/","title":"In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial","quote":"In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://www.neurology.org/doi/10.1212/WNL.0000000000005255","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","quote":"Elamipretide increased exercise performance after 5 days of treatment in patients with PMM without increased safety concerns.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.126.014397","title":"Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model","quote":"Elamipretide improved whole muscle contractile function and prevented atrophy development.","link_status":"http_403","quote_status":"unverified"},{"id":"s5","type":"pubmed","url":"https://physoc.onlinelibrary.wiley.com/doi/10.14814/phy2.15266","title":"SS‐31 does not prevent or reduce muscle atrophy 7 days after a 65 kdyne contusion spinal cord injury in young male mice","quote":"SS-31 did not preserve body mass or hindlimb muscle mass 7 days post-SCI.","link_status":"ok","quote_status":"unverified"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/cfs/comments/1j2upcm/my_experience_treating_my_mecfs_with/","title":"My Experience Treating my ME/CFS with mitochondrial peptides","quote":"i notice very dramatic improvement to muscle strength on the ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":19688,"tokens_out":2926,"cost":0.031925,"prev_hash":"genesis","hash":"82886ea729cf6b45cecfe78d1d4adc86af52a245806fadc33613fe13de1433f6"}],"provenance":[{"ts":"2026-06-29T23:51:53.770Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Muscle Loss\nSlug: ss-31-muscle-loss\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **SS-31 (Elamipretide)** → mitochondrial\",\"section_headings\":[\"What's breaking down\",\"Why SS-31 (Elamipretide) might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do no","response":"{\n  \"slug\": \"ss-31-muscle-loss\",\n  \"title\": \"SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown\",\n  \"body\": \"## What's breaking down\\n\\nMuscle loss with age, often called sarcopenia, involves multiple layers. One key layer is mitochondrial decline inside muscle cells. Mitochondria produce ATP for contraction and repair. With age, they generate more reactive oxygen species, lose efficiency in oxidative phosphorylation, and show reduced ADP sensitivity. This leads to lower energy output, oxidative damage to proteins, and impaired muscle performance and maintenance. If mitochondrial dysfunction outpaces repair mechanisms, muscle mass and strength decline over time.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\n1. If mitochondrial oxidative stress and poor ATP production contribute to your muscle loss, SS-31 binds cardiolipin in the inner mitochondrial membrane. 2. This stabilizes the membrane, improves electron transport chain efficiency, and lowers excess ROS production. 3. Therefore for you: If that layer is part of your problem, SS-31 is discussed because it targets repair (tissue) — not because it masks pain. 4. Better mitochondrial function can support muscle fiber maintenance and fatigue resistance instead of allowing further breakdown.\\n\\n## How these fit together\\n\\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer of degeneration. If your profile includes other layers like inflammation or hormonal decline, additional approaches would address those separately.\\n\\n## What the evidence actually shows\\n\\nPreclinical studies in aged mice show SS-31 improves skeletal muscle mitochondrial ATP production, reverses age-related redox stress, increases fatigue resistance, and boosts exercise tolerance (Campbell et al. 2019; Siegel et al. 2013). One 2026 rat model of HFpEF found it improved soleus and EDL muscle contractile function and prevented atrophy development. A 2022 mouse study after spinal cord injury found no pre","tokens_in":19688,"tokens_out":2926,"cost":0,"prev":"genesis","hash":"1369e0bd23f42dc3d720becb7e4fecdf3c0ce157788a4eb0d95f6fd8a47287cd"},{"ts":"2026-07-17T02:42:05.916Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-muscle-loss","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1369e0bd23f42dc3d720becb7e4fecdf3c0ce157788a4eb0d95f6fd8a47287cd","hash":"50172c91001aedb95ad7ba36fe0e7c20a285d46358a7686b2d3ab41118ec8264"},{"ts":"2026-08-05T10:15:08.233Z","model":"claude-opus-5","action":"citation-identity-repair","why":"","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"50172c91001aedb95ad7ba36fe0e7c20a285d46358a7686b2d3ab41118ec8264","hash":"f6860d14309d3bbcbc3eb313bc506ae42c5c28469893d28628cf6e611a98d3d5"}],"energy":{"passes":3,"tokens_in":19688,"tokens_out":2926,"tokens_total":22614,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1,"claude-opus-5":1},"head":"f6860d14309d3bbcbc3eb313bc506ae42c5c28469893d28628cf6e611a98d3d5"},"posted_at":"2026-06-29T21:33:23.485Z","created_at":"2026-06-29T21:33:23.485Z","updated_at":"2026-08-05T10:15:08.233Z","machine":{"shape":"article.machine/v1","slug":"ss-31-muscle-loss","kind":"article","read":{"human":"https://miscsubjects.com/a/ss-31-muscle-loss","json":"https://miscsubjects.com/api/articles/ss-31-muscle-loss","bundle":"https://miscsubjects.com/api/articles/ss-31-muscle-loss/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":6,"sources":6,"contributions":1,"revisions":2,"objections_url":"https://miscsubjects.com/api/articles/ss-31-muscle-loss/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=ss-31-muscle-loss","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-muscle-loss\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-muscle-loss\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/ss-31-muscle-loss/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"ss-31-muscle-loss\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/ss-31-muscle-loss | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/ss-31-muscle-loss","json":"/api/articles/ss-31-muscle-loss","markdown":"/api/articles/ss-31-muscle-loss/bundle?format=markdown","skill":"/api/articles/ss-31-muscle-loss/skill","topology":"/api/articles/ss-31-muscle-loss/topology","versions":"/api/articles/ss-31-muscle-loss/revisions","invocations":"/api/articles/ss-31-muscle-loss/invocations"},"editorial_review":null,"editorial_audit":{"slug":"ss-31-muscle-loss","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"ae662a05c724f37d2730f2015b610bc85feb5ca9d247b160da3a0e34c5a9016c","object":{"object_type":"article-object","identity":{"id":"article:ss-31-muscle-loss","slug":"ss-31-muscle-loss","title":"SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/ss-31-muscle-loss","role":"explain","audience":"human"},"skill":{"route":"/api/articles/ss-31-muscle-loss/skill","role":"direct behavior","audience":"model","content":"---\nname: ss-31-muscle-loss\ndescription: Apply the SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown\n\nThis Skill is the behavioral expression of [the canonical article](/a/ss-31-muscle-loss). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/ss-31-muscle-loss.\n- Read claims and relationships at /api/articles/ss-31-muscle-loss/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Muscle loss with age, often called sarcopenia, involves multiple layers. One key layer is mitochondrial decline inside muscle cells. Mitochondria produce ATP for contraction and repair. With age, they generate more reac\n\n## Representations\n\n- Human: /a/ss-31-muscle-loss\n- JSON: /api/articles/ss-31-muscle-loss\n- Relationships: /api/articles/ss-31-muscle-loss/topology\n- History: /api/articles/ss-31-muscle-loss/revisions\n"},"json":{"route":"/api/articles/ss-31-muscle-loss","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/ss-31-muscle-loss/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","ss","31","muscle","loss"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/ss-31-muscle-loss/invocations?status=success","failure_events":"/api/articles/ss-31-muscle-loss/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"ss-31-muscle-loss","title":"SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown","body":"## What's breaking down\n\nMuscle loss with age, often called sarcopenia, involves multiple layers. One key layer is mitochondrial decline inside muscle cells. Mitochondria produce ATP for contraction and repair. With age, they generate more reactive oxygen species, lose efficiency in oxidative phosphorylation, and show reduced ADP sensitivity. This leads to lower energy output, oxidative damage to proteins, and impaired muscle performance and maintenance. If mitochondrial dysfunction outpaces repair mechanisms, muscle mass and strength decline over time.\n\n## Why SS-31 (Elamipretide) might help you\n\n1. If mitochondrial oxidative stress and poor ATP production contribute to your muscle loss, SS-31 binds cardiolipin in the inner mitochondrial membrane. 2. This stabilizes the membrane, improves electron transport chain efficiency, and lowers excess ROS production. 3. Therefore for you: If that layer is part of your problem, SS-31 is discussed because it targets repair (tissue) — not because it masks pain. 4. Better mitochondrial function can support muscle fiber maintenance and fatigue resistance instead of allowing further breakdown.\n\n## How these fit together\n\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer of degeneration. If your profile includes other layers like inflammation or hormonal decline, additional approaches would address those separately.\n\n## What the evidence actually shows\n\nPreclinical studies in aged mice show SS-31 improves skeletal muscle mitochondrial ATP production, reverses age-related redox stress, increases fatigue resistance, and boosts exercise tolerance (Campbell et al. 2019; Siegel et al. 2013). One 2026 rat model of HFpEF found it improved soleus and EDL muscle contractile function and prevented atrophy development. A 2022 mouse study after spinal cord injury found no prevention of muscle atrophy at 7 days. Human data: A randomized trial showed a single dose improved in vivo mitochondrial ATP production in older adult skeletal muscle. Phase 2 trials in primary mitochondrial myopathy showed some exercise gains; phase 3 did not meet primary endpoints on walking distance. In Barth syndrome (mitochondrial cardiolipin disorder with muscle weakness), long-term data supported accelerated approval for muscle strength improvement.\n\n## What scientists say\n\nResearchers note SS-31 rapidly improves ADP sensitivity in aged mitochondria via the adenine nucleotide translocator and stabilizes cardiolipin. They highlight benefits for mitochondrial myopathies and age-related muscle function but emphasize mixed human trial results outside specific genetic conditions. Preclinical consistency on energetics contrasts with translation challenges in broader sarcopenia.\n\n## What people say on Reddit\n\nAnecdotal reports in ME/CFS communities mention perceived muscle strength gains in isolated cases, with one user noting dramatic improvement allowing weight lifting. Others report no noticeable effect or discuss cost barriers from trial doses around 40 mg daily. Discussions often reference mitochondrial myopathy trials and stress pacing alongside any use.\n\n## What people say on X\n\nLimited public posts discuss SS-31 primarily in context of mitochondrial disorders or research updates; few direct anecdotes on general muscle loss appear in recent searches.\n\n## What we do not know\n\nNo large human trials specifically target age-related sarcopenia or general muscle loss. Long-term effects on muscle mass versus function remain unclear outside rare diseases. Optimal duration, combination strategies, and identification of responders based on mitochondrial status need more data.\n\n## Safety and limits\n\nClinical trials report generally good tolerability with subcutaneous or IV administration. Some phase 3 programs showed no major safety signals but lacked efficacy on primary measures. Individual responses vary; it is not approved for general muscle loss. Evidence is strongest in mitochondrial-specific conditions.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/ss-31-muscle-loss/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"SS-31 improves mitochondrial ATP production and exercise tolerance in aged mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Supports mitochondrial repair mechanism for muscle energetics.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A single dose of elamipretide improved in vivo mitochondrial ATP production in older adult skeletal muscle in a randomized trial.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Direct human evidence on mitochondrial function in aging muscle.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet primary endpoints on walking distance or fatigue.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Highlights limits of translation from preclinical to broad human use.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"In a 2026 HFpEF rat model, elamipretide improved muscle contractile function and prevented atrophy.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Recent model linking mitochondrial stabilization to anti-atrophy effects.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"SS-31 did not prevent muscle atrophy 7 days post-SCI in young male mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Shows context-specific limits of benefit.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Anecdotal reports on Reddit include perceived muscle strength gains in some ME/CFS users.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6588449/","title":"Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice","quote":"Treatment with SS-31 restores redox homeostasis, improves mitochondrial quality, and increases exercise tolerance without an increase in mitochondrial content.","summary":"Aged mice study showing mitochondrial and functional muscle benefits.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:51:52.225Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"8dee10a450c5984e52e5a1d663165c59104ca847cae033a249af83eadc8fcad1"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/34264994/","title":"In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial","quote":"In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.","summary":"Identifier corrected 2026-08-05: it read PMID 34242343, which is \"The experiences of family caregivers of people with severe mental illness in the Middle East\". Verified against PubMed that 34264994 is the paper this citation names. Human randomized trial on ATP in aging muscle.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:51:52.225Z","link_status":"ok","quote_status":"unverified","prev":"8dee10a450c5984e52e5a1d663165c59104ca847cae033a249af83eadc8fcad1","hash":"01293e026cd0d26861573930fba64242b2f06b4563c1c4f8a85de8e0e25ba4ca","pmid":"34264994","external_id":"34264994"},{"id":"s3","type":"pubmed","url":"https://www.neurology.org/doi/10.1212/WNL.0000000000005255","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","quote":"Elamipretide increased exercise performance after 5 days of treatment in patients with PMM without increased safety concerns.","summary":"Phase 1/2 and later phase 3 context for PMM.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:51:52.225Z","link_status":"ok","quote_status":"unverified","prev":"01293e026cd0d26861573930fba64242b2f06b4563c1c4f8a85de8e0e25ba4ca","hash":"5ad5d241696237be2b0c6e3943516cf1be0e7340a6e8f77c49371d1c80a36ec1"},{"id":"s4","type":"pubmed","url":"https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.126.014397","title":"Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model","quote":"Elamipretide improved whole muscle contractile function and prevented atrophy development.","summary":"2026 rat study on muscle performance and atrophy prevention.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:51:52.225Z","link_status":"http_403","quote_status":"unverified","prev":"5ad5d241696237be2b0c6e3943516cf1be0e7340a6e8f77c49371d1c80a36ec1","hash":"13b522947f9e8afec6291d738a93503b9fb160230d6909f0d3fa98a6da012102"},{"id":"s5","type":"pubmed","url":"https://physoc.onlinelibrary.wiley.com/doi/10.14814/phy2.15266","title":"SS‐31 does not prevent or reduce muscle atrophy 7 days after a 65 kdyne contusion spinal cord injury in young male mice","quote":"SS-31 did not preserve body mass or hindlimb muscle mass 7 days post-SCI.","summary":"Negative finding in SCI atrophy model.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:51:52.225Z","link_status":"ok","quote_status":"unverified","prev":"13b522947f9e8afec6291d738a93503b9fb160230d6909f0d3fa98a6da012102","hash":"4e13a4e4433ac3fe59e2efcea885e527a8f60b57299915d5f28a63cfe56f5073"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/cfs/comments/1j2upcm/my_experience_treating_my_mecfs_with/","title":"My Experience Treating my ME/CFS with mitochondrial peptides","quote":"i notice very dramatic improvement to muscle strength on the ...","summary":"User reports of muscle strength changes with SS-31.","claim_ids":["c6"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:51:52.225Z","link_status":"ok","quote_status":"unverified","prev":"4e13a4e4433ac3fe59e2efcea885e527a8f60b57299915d5f28a63cfe56f5073","hash":"53f250a3b6773314314d08c8996c3cc9e05d3c63b39dd116dac4e1ed798d0ab0"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":2,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:51:53.770Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown","register":"source_ledger","body":"## What's breaking down\n\nMuscle loss with age, often called sarcopenia, involves multiple layers. One key layer is mitochondrial decline inside muscle cells. Mitochondria produce ATP for contraction and repair. With age, they generate more reactive oxygen species, lose efficiency in oxidative phosphorylation, and show reduced ADP sensitivity. This leads to lower energy output, oxidative damage to proteins, and impaired muscle performance and maintenance. If mitochondrial dysfunction outpaces repair mechanisms, muscle mass and strength decline over time.\n\n## Why SS-31 (Elamipretide) might help you\n\n1. If mitochondrial oxidative stress and poor ATP production contribute to your muscle loss, SS-31 binds cardiolipin in the inner mitochondrial membrane. 2. This stabilizes the membrane, improves electron transport chain efficiency, and lowers excess ROS production. 3. Therefore for you: If that layer is part of your problem, SS-31 is discussed because it targets repair (tissue) — not because it masks pain. 4. Better mitochondrial function can support muscle fiber maintenance and fatigue resistance instead of allowing further breakdown.\n\n## How these fit together\n\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer of degeneration. If your profile includes other layers like inflammation or hormonal decline, additional approaches would address those separately.\n\n## What the evidence actually shows\n\nPreclinical studies in aged mice show SS-31 improves skeletal muscle mitochondrial ATP production, reverses age-related redox stress, increases fatigue resistance, and boosts exercise tolerance (Campbell et al. 2019; Siegel et al. 2013). One 2026 rat model of HFpEF found it improved soleus and EDL muscle contractile function and prevented atrophy development. A 2022 mouse study after spinal cord injury found no prevention of muscle atrophy at 7 days. Human data: A randomized trial showed a single dose improved in vivo mitochondrial ATP production in older adult skeletal muscle. Phase 2 trials in primary mitochondrial myopathy showed some exercise gains; phase 3 did not meet primary endpoints on walking distance. In Barth syndrome (mitochondrial cardiolipin disorder with muscle weakness), long-term data supported accelerated approval for muscle strength improvement.\n\n## What scientists say\n\nResearchers note SS-31 rapidly improves ADP sensitivity in aged mitochondria via the adenine nucleotide translocator and stabilizes cardiolipin. They highlight benefits for mitochondrial myopathies and age-related muscle function but emphasize mixed human trial results outside specific genetic conditions. Preclinical consistency on energetics contrasts with translation challenges in broader sarcopenia.\n\n## What people say on Reddit\n\nAnecdotal reports in ME/CFS communities mention perceived muscle strength gains in isolated cases, with one user noting dramatic improvement allowing weight lifting. Others report no noticeable effect or discuss cost barriers from trial doses around 40 mg daily. Discussions often reference mitochondrial myopathy trials and stress pacing alongside any use.\n\n## What people say on X\n\nLimited public posts discuss SS-31 primarily in context of mitochondrial disorders or research updates; few direct anecdotes on general muscle loss appear in recent searches.\n\n## What we do not know\n\nNo large human trials specifically target age-related sarcopenia or general muscle loss. Long-term effects on muscle mass versus function remain unclear outside rare diseases. Optimal duration, combination strategies, and identification of responders based on mitochondrial status need more data.\n\n## Safety and limits\n\nClinical trials report generally good tolerability with subcutaneous or IV administration. Some phase 3 programs showed no major safety signals but lacked efficacy on primary measures. Individual responses vary; it is not approved for general muscle loss. Evidence is strongest in mitochondrial-specific conditions.","claims":[{"id":"c1","text":"SS-31 improves mitochondrial ATP production and exercise tolerance in aged mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Supports mitochondrial repair mechanism for muscle energetics.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A single dose of elamipretide improved in vivo mitochondrial ATP production in older adult skeletal muscle in a randomized trial.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Direct human evidence on mitochondrial function in aging muscle.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet primary endpoints on walking distance or fatigue.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Highlights limits of translation from preclinical to broad human use.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"In a 2026 HFpEF rat model, elamipretide improved muscle contractile function and prevented atrophy.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Recent model linking mitochondrial stabilization to anti-atrophy effects.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"SS-31 did not prevent muscle atrophy 7 days post-SCI in young male mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Shows context-specific limits of benefit.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Anecdotal reports on Reddit include perceived muscle strength gains in some ME/CFS users.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Real-world user experience separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:51:53.167Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6588449/","title":"Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice","quote":"Treatment with SS-31 restores redox homeostasis, improves mitochondrial quality, and increases exercise tolerance without an increase in mitochondrial content.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/34242343/","title":"In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial","quote":"In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://www.neurology.org/doi/10.1212/WNL.0000000000005255","title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","quote":"Elamipretide increased exercise performance after 5 days of treatment in patients with PMM without increased safety concerns.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.126.014397","title":"Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model","quote":"Elamipretide improved whole muscle contractile function and prevented atrophy development.","link_status":"http_403","quote_status":"unverified"},{"id":"s5","type":"pubmed","url":"https://physoc.onlinelibrary.wiley.com/doi/10.14814/phy2.15266","title":"SS‐31 does not prevent or reduce muscle atrophy 7 days after a 65 kdyne contusion spinal cord injury in young male mice","quote":"SS-31 did not preserve body mass or hindlimb muscle mass 7 days post-SCI.","link_status":"ok","quote_status":"unverified"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/cfs/comments/1j2upcm/my_experience_treating_my_mecfs_with/","title":"My Experience Treating my ME/CFS with mitochondrial peptides","quote":"i notice very dramatic improvement to muscle strength on the ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":19688,"tokens_out":2926,"cost":0.031925,"prev_hash":"genesis","hash":"82886ea729cf6b45cecfe78d1d4adc86af52a245806fadc33613fe13de1433f6"}],"provenance":[{"ts":"2026-06-29T23:51:53.770Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Muscle Loss\nSlug: ss-31-muscle-loss\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **SS-31 (Elamipretide)** → mitochondrial\",\"section_headings\":[\"What's breaking down\",\"Why SS-31 (Elamipretide) might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do no","response":"{\n  \"slug\": \"ss-31-muscle-loss\",\n  \"title\": \"SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown\",\n  \"body\": \"## What's breaking down\\n\\nMuscle loss with age, often called sarcopenia, involves multiple layers. One key layer is mitochondrial decline inside muscle cells. Mitochondria produce ATP for contraction and repair. With age, they generate more reactive oxygen species, lose efficiency in oxidative phosphorylation, and show reduced ADP sensitivity. This leads to lower energy output, oxidative damage to proteins, and impaired muscle performance and maintenance. If mitochondrial dysfunction outpaces repair mechanisms, muscle mass and strength decline over time.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\n1. If mitochondrial oxidative stress and poor ATP production contribute to your muscle loss, SS-31 binds cardiolipin in the inner mitochondrial membrane. 2. This stabilizes the membrane, improves electron transport chain efficiency, and lowers excess ROS production. 3. Therefore for you: If that layer is part of your problem, SS-31 is discussed because it targets repair (tissue) — not because it masks pain. 4. Better mitochondrial function can support muscle fiber maintenance and fatigue resistance instead of allowing further breakdown.\\n\\n## How these fit together\\n\\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer of degeneration. If your profile includes other layers like inflammation or hormonal decline, additional approaches would address those separately.\\n\\n## What the evidence actually shows\\n\\nPreclinical studies in aged mice show SS-31 improves skeletal muscle mitochondrial ATP production, reverses age-related redox stress, increases fatigue resistance, and boosts exercise tolerance (Campbell et al. 2019; Siegel et al. 2013). One 2026 rat model of HFpEF found it improved soleus and EDL muscle contractile function and prevented atrophy development. A 2022 mouse study after spinal cord injury found no pre","tokens_in":19688,"tokens_out":2926,"cost":0,"prev":"genesis","hash":"1369e0bd23f42dc3d720becb7e4fecdf3c0ce157788a4eb0d95f6fd8a47287cd"},{"ts":"2026-07-17T02:42:05.916Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-muscle-loss","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1369e0bd23f42dc3d720becb7e4fecdf3c0ce157788a4eb0d95f6fd8a47287cd","hash":"50172c91001aedb95ad7ba36fe0e7c20a285d46358a7686b2d3ab41118ec8264"},{"ts":"2026-08-05T10:15:08.233Z","model":"claude-opus-5","action":"citation-identity-repair","why":"","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"50172c91001aedb95ad7ba36fe0e7c20a285d46358a7686b2d3ab41118ec8264","hash":"f6860d14309d3bbcbc3eb313bc506ae42c5c28469893d28628cf6e611a98d3d5"}],"energy":{"passes":3,"tokens_in":19688,"tokens_out":2926,"tokens_total":22614,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1,"claude-opus-5":1},"head":"f6860d14309d3bbcbc3eb313bc506ae42c5c28469893d28628cf6e611a98d3d5"},"posted_at":"2026-06-29T21:33:23.485Z","created_at":"2026-06-29T21:33:23.485Z","updated_at":"2026-08-05T10:15:08.233Z","machine":{"shape":"article.machine/v1","slug":"ss-31-muscle-loss","kind":"article","read":{"human":"https://miscsubjects.com/a/ss-31-muscle-loss","json":"https://miscsubjects.com/api/articles/ss-31-muscle-loss","bundle":"https://miscsubjects.com/api/articles/ss-31-muscle-loss/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":6,"sources":6,"contributions":1,"revisions":2,"objections_url":"https://miscsubjects.com/api/articles/ss-31-muscle-loss/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=ss-31-muscle-loss","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-muscle-loss\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"ss-31-muscle-loss\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/ss-31-muscle-loss/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"ss-31-muscle-loss\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/ss-31-muscle-loss | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/ss-31-muscle-loss","json":"/api/articles/ss-31-muscle-loss","markdown":"/api/articles/ss-31-muscle-loss/bundle?format=markdown","skill":"/api/articles/ss-31-muscle-loss/skill","topology":"/api/articles/ss-31-muscle-loss/topology","versions":"/api/articles/ss-31-muscle-loss/revisions","invocations":"/api/articles/ss-31-muscle-loss/invocations"},"editorial_review":null,"editorial_audit":{"slug":"ss-31-muscle-loss","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"ae662a05c724f37d2730f2015b610bc85feb5ca9d247b160da3a0e34c5a9016c"}}}